The use of BX-912 for treatment of pulmonary hypertension
BX-912, a small-molecule PDK1 inhibitor, addresses the challenges of pulmonary hypertension by increasing SOX17 expression and restoring pathway activity, providing a mechanism-anchored treatment with improved efficacy and tolerability, particularly for PAH, through oral administration and companion diagnostics.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- RHODE ISLAND HOSPITAL
- Filing Date
- 2025-11-21
- Publication Date
- 2026-05-28
AI Technical Summary
Pulmonary hypertension, particularly pulmonary arterial hypertension (PAH), remains a progressive and incurable disorder with delayed diagnosis and suboptimal therapeutic responses, lacking mechanism-anchored, orally deliverable treatments that modify disease and enable rational patient selection.
The use of BX-912, a small-molecule PDK1 inhibitor, administered orally or via alternative routes, to increase SOX17 expression and restore SOX17-regulated pathway activity in pulmonary endothelial cells, combined with dosing regimens and companion diagnostics for patient selection based on SOX17 status, to treat and potentially prevent PH.
BX-912 treatment reduces disease severity and susceptibility by improving hemodynamic parameters, offering a comprehensive solution with reduced side effects and improved patient selection and monitoring.
Smart Images
Figure IMGF000008_0001 
Figure IMGF000075_0001 
Figure 00000084_0000